


HCV





RESISTANCE

ADVISORY



March 24, 2009



HISTORY

- Purpose: bring together parties interested in and working in HCV drug resistance to discuss issues pertinent to HCV drug development and resistance testing
 - Outgrowth of proposal at the 1st International Workshop on Hepatitis C: Resistance and New Compounds (October, 2006)
 - Ad hoc group approached the Forum for Collaborative HIV Research for organizational support
 - Composition: representatives from industry, academics and regulatory agencies

Goals:

- Produce consensus recommendations of appropriate methodology for HCV resistance testing
 - For drug development
 - For clinical practice
- Provide scientific guidance to facilitate discussion between industry and regulatory agencies in areas of HCV drug resistance



HISTORY

- 1st meeting: May 18, 2007, Washington, DC
 - Identified and classified questions/issues:
 - Formed working groups
 - Sequence Analysis Working Group (SAWG)
 - Phenotype Working Group (PWG)
 - Clinical Working Group (CWG)
 - Other (eg, Database)
- 2nd meeting: Nov 2, 2007, Boston, MA
 - Progress reports and discussion from three working groups
 - SAWG and PWG encouraged to proceed toward preparation of manuscripts
 - HCV DRAG presentation at 2007 HepDART meeting
 - Continued discussion of clinical issues
 - Decision to move toward formation of Database Working Group
- 3rd meeting: February 13, 2008, Paris, France
 - 3 HCV databases represented
 - Japanese, European and Los Alamos
 - Discussion on collaborative approaches for HCV resistance db



PROGRESS

- Presentations
 - HCV Resistance Workshop, Nov 2007
 - HepDart, Dec 2007
 - EASL Hep B and C Resistance Conference, Feb 2008
- Manuscripts
 - SAWG
 - October 2008: First draft assembled and delivered to OC after multiple versions and telecons between SAWG members
 - Oct 2008 Jan 2009: Editing by HCV DRAG OC members
 - March 2009: Penultimate draft sent to SWAG members and OC members for final comments/editing
 - April 2009: Target submission date
 - Target journal: Gastroenterology
 - PWG
 - Draft manuscript in preparation
 - Target journal and date: tbd



TODAY'S MEETING

- Consideration of drug resistance in the drug development process and clinical trial design
 - Lessons learned
 - Regulatory perspective
 - Persistence and long-term follow-up
- HCV: where virology and hepatology intersect
- HCV databases
 - Resistance literature repository
 - HCV sequences
- HCV resistance CME



NEXT STEPS

- New leader for phenotype working group
- Reorganization of clinical working group
- Create ResistLit DB WG (Resistance Literature Database working group)
- Create HCV resistance CME working group
- Next steps on collaborative HCV resistance database
- Publication of meeting outcomes (manuscript #3)
- Next meeting (autumn 2009)
 - Focus topic



PROCESS

- Define issue and questions
- Categorize into one of following:
 - 1. Immediate recommendation needed to guide process in right direction
 - 2. Recommendation based on discussions within working groups and between WG's and DRAG
 - 3. Multiple possibilities to be described by working group with pro/con and context
 - 4. Insufficient data/methodology at this time, noted as issue